FUNDAMENTALS · Fundamentals · AU Healthcare

Actinogen Medical (ACW) Fundamentals 2026 — Revenue Analysis | SniperIQ

Actinogen Medical (ACW) is a AU-listed Healthcare company in Biotechnology with a market capitalization of A

52M, trading at A$0.04 on the ASX. This SniperIQ fundamentals page covers Actinogen Medical's valuation, profitability (net margin -326.3%), revenue (A$5M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market CapA
52M
Net Margin-326.3%
Revenue (FY25)A$5M

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is Actinogen Medical's market cap?

Actinogen Medical (ACW) has a market capitalization of approximately A

52M, trading at A$0.04 on the ASX. Market cap moves with the live share price.

What is Actinogen Medical's P/E ratio?

Actinogen Medical's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 15.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Actinogen Medical?

Actinogen Medical runs a net profit margin of -326.3%, a gross margin of 96.2%, and an operating margin of -365.3%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Actinogen Medical generate?

Actinogen Medical reported revenue of A$5M for fiscal year 2025, with net income of -A

5M and earnings per share (EPS) of -0.0049. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Actinogen Medical pay a dividend?

Actinogen Medical does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Actinogen Medical financially healthy?

Actinogen Medical carries a debt-to-equity ratio of 0.04x and a current ratio of 4.19x, with a market beta of 0.85. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Actinogen Medical a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Actinogen Medical (ACW) the key facts are: market cap A

52M, revenue A$5M, 52-week range 0.023-0.072. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Actinogen Medical's full fundamentals live

Get Actinogen Medical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: ADC Therapeutics (ADCT) fundamentals · EMVision Medical Devices (EMV) fundamentals · Orthocell (OCC) fundamentals · Qatari German Company for Medical Devices (Q.P.S.C.) (QGMD.QA) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons